FDA draft guidelines for the clinical evaluation of antiinflammatory and antirheumatic drugs in children. Executive summary

Arthritis Rheum. 1995 May;38(5):715-8. doi: 10.1002/art.1780380522.

Authors

E H Giannini¹, D J Lovell, B Hepburn

Affiliation

¹ Children's Hospital Medical Center, University of Cincinnati College of Medicine, Ohio, USA.

PMID: 7748227
DOI: 10.1002/art.1780380522

No abstract available

Publication types

Guideline
Practice Guideline

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Juvenile / drug therapy*
Child
Child, Preschool
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Consumer Product Safety
Drug Evaluation
Drug Therapy, Combination
Humans
Infant
Infant, Newborn
Time Factors
Treatment Outcome
United States
United States Food and Drug Administration

Substances

Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents